niche-3 of nivolumab and relatlimab in dmmr colon cancer compared to niche-2
Published 1 month ago • 75 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
2:46
#esmo22 highlights on neoadjuvant ici in locally advanced dmmr colon cancer: the niche-2 study
-
0:58
niche-2: nivolumab and ipilimumab in non-metastatic msi-high colon cancer
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
1:04
phase ii trial of nivolumab and relatlimab in mss crc
-
0:11
life of young colon cancer survivor
-
7:29
myriam chalabi, esmo 2022: neoadjuvant immune checkpoint inhibition in mmr-deficient colon cancer
-
0:15
colon cancer symptoms to look out for
-
1:01
stage iv colon cancer patient tells his story
-
1:09
phase ii trial of nivolumab to chemoradiotherapy in non-metastatic mibc
-
7:09
relativity-047: relatlimab (rela) plus nivolumab (nivo) versus nivo in first-line advanced melanoma
-
1:48
colorectal cancer laparoscopic surgery - 3d animation
-
0:47
from stage iv colon cancer diagnosis to survivorship
-
0:49
warning signs of colon cancer.
-
5:23
adjuvant therapy for stage ii and iii colon cancer
-
0:16
stuart shares some of the symptoms he experienced while living with bowel cancer. #bowelcancer
-
0:57
t staging for rectal cancer
-
0:06
signs and symptoms of colorectal cancer
-
4:15
colon cancer: a new prognostic and predictive tool
-
24:05
what's new in colorectal cancer treatment? by michael hall, md, ms